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Abstract 
Uncontrolled, excessive production of pro-inflammatory mediators from immune cells and 
traumatized tissues can cause systemic inflammatory issues like sepsis, one of the ten leading 
causes of death in the United States and one of the three leading causes of death in the intensive 
care unit. Understanding the effects of inflammation on the autonomic control system can improve 
a patient’s chance of recovery after an inflammatory event such as surgery. Though the effects of 
the autonomic response on the inflammatory system are well defined, there remains a gap in 
understanding the reverse response. Specifically, the impact of the inflammatory response on the 
autonomic control system remains unknown. In this study, we investigate hypothesized 
interactions of the inflammatory system with the thermal and cardiovascular regulatory systems in 
response to an endotoxin challenge using mathematical modeling. We calibrate the model to data 
from two independent studies: a) of the inflammatory response in healthy young men and b) a 
comparative study of the inflammatory response between mice and humans. Simulation analysis 
is used to explore how the model responds to pathological input and treatment, specifically 
antibiotics, antipyretics, vasopressors, and combination therapy. Our findings show that 
multimodal treatment that simultaneously targets both the pathogen and the infection symptoms 
gives the most favorable recovery outcome. 
New & Noteworthy  
This study introduces an innovative computational model incorporating the behavior and 
interactions of inflammation, temperature, pain, HR, and BP in response to an endotoxin challenge. 
We use sensitivity analysis and subset selection to identify parameters that can be estimated given 
the model and data and use nonlinear least squares optimization to calibrate the model to data from 
two independent clinical studies. Optimal parameters are used to predict how patients may respond 
to antibiotics, antipyretics, vasopressors, and a combination therapy. Results of our study reveal 
that the inflammatory response to a pathogen challenge elevates temperature, causing an increase 
in HR on a timescale of hours, and that temperature plays a vital role in the interaction between 
BP and HR. Moreover, we show that during an infection, treatment with antibiotics, antipyretics, 
vasopressors, and combinations of these acts to down-regulate HR in a temperature-dependent 
fashion.  
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BP         Blood pressure  
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Introduction 
Systemic inflammation is comorbid with various diseases including diabetes (64), cancer (14), 
heart disease (66), and sepsis (29, 30), and it plays a prominent role in eight out of the ten leading 
causes of death in the U.S. (28). The action of inflammation is multi-faceted and impacts multiple 
organ systems, such as the digestive, respiratory, endocrine, and nervous systems.  In this study, 
we use mathematical modeling to explore how the inflammatory response to a pathogen challenge 
interacts with the thermal, pain perception, and cardiovascular systems. Our goal is to examine the 
effect on cytokine concentrations, body temperature, pain, heart rate (HR), and blood pressure 
(BP). We focus on hemodynamic quantities that are routinely collected at both in- and out-patient 
facilities, measured non-invasively at a high sampling rate, and interpreted within minutes. We 
hypothesize that the hemodynamic signals correlate with inflammatory markers, and therefore 
have the potential to inform the development of clinical protocols important for early detection of 
pathological conditions such as sepsis. Understanding how hemodynamics change with 
inflammation is also of great importance in devising more effective treatment strategies to improve 
recovery outcomes for patients.  
 Numerous in-vivo biological studies in mice and rats have investigated the effects of 
autonomic control on the inflammatory system (56, 57). Borovikova et al. (5) discovered the 
cholinergic anti-inflammatory pathway modulating the immune response via the local release of 
acetylcholine from vagal fibers in target tissues. They found that an increase in vagal activity 
results in a decrease in the pro-inflammatory cytokines tumor necrosis factor-𝛼 (TNF-𝛼), 
interleukin 6 (IL-6), and interleukin 1𝛽 (IL-1𝛽). Following this, Tracey (57) found that the 
production of cytokines in response to inflammation activates afferent firing to the brain, and that 
subsequent vagal efferent activation inhibits cytokine synthesis. This inflammation-sensing and 
inflammation-suppressing network, dubbed the inflammatory reflex, explains how the autonomic 
control and inflammatory systems work synergistically to maintain homeostasis of the 
inflammatory response. The study by Tracey (57) did an excellent job describing the impact of the 
autonomic control on inflammation, but it did not describe how changes in autonomic regulation, 
triggered by inflammation, impact hemodynamics. 
Previous studies have used modeling to explore the inflammatory response to an endotoxin 
challenge in rodents in conjunction with in-vivo experimental data. Seminal studies include 
contributions by Chow et al. (10) who modeled immunocytes, nitric oxide (NO) byproducts, and 
three distinct cytokines to investigate the acute inflammation response to a bolus administration of 
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the bacterial endotoxin lipopolysaccharide (LPS). The Chow et al. study demonstrated that three 
different triggers (infection, surgery, and hemorrhage) engage a universal cascade of immune 
signals, whose behavior and magnitude of activity differ among the shock states. A similar model 
by Daun et al. (15) studied how different tissue damage levels in rats affect cytokine behavior, and 
Prince et al. (47) examined the trauma-induced inflammatory pathway of mice deficient in CD14, 
a molecule in immune cell receptors used for LPS recognition.  
While the above investigations (10, 15, 47) revealed essential features of the immune 
reaction to pathogens in rodents, they do not elucidate how the inflammatory system interacts with 
the cardiovascular, thermal, and pain systems. Moreover, it is well known that the inflammatory 
pathways differ between rodents and humans (54) and that rodents tolerate much higher levels of 
pathogens (17). Experimental observations by Copeland et al. (13) demonstrated this by 
administering LPS to humans and mice at doses (2 ng/kg of body weight for humans and 500 ng/kg 
for mice) eliciting equivalent IL-6 plasma concentrations 2 hours post-injection. Their results 
showed that humans experienced fever as well as an increase in HR and systolic BP, while the 
mice had no fever or changes in HR and BP. These results demonstrate that investigations in mice 
do not have direct applicability to humans. New models are needed to effectively explore the 
differences between the two species and to gain insight into thermal regulation and cardiovascular 
functions.  
Several studies have used models to examine inflammatory-cardiovascular communication 
in humans (18, 52). Foteinou et al. (18) employed a multi-scale mathematical model to predict the 
parasympathetic activity and HR in human subjects who received a dose of LPS (2 ng/kg of body 
weight) alone or in combination with an epinephrine infusion. This study assessed parasympathetic 
activity via calculations of the heart rate variability (HRV) index pNN50, which measures the 
percentage of differences of successive inter-beat intervals greater than 50 ms (18). Scheff et al. 
(52) expanded this model by incorporating regulation of immune activity via hormonal circadian 
rhythms. They showed that circadian variability in inflammation correlates with daily patterns in 
HR and HRV (52). While the investigations of Foteinou et al. (18) and Scheff et al. (52) reflect 
the complexity of inflammatory-cardiac interactions, they do not account for thermal and pain  
regulation and the impact on hemodynamics. 
As the body battles infection the threshold for pain perception decreases (2, 13, 31, 63), 
and the release of inflammatory cytokines, in particular, IL-6 and TNF-𝛼, raises core temperature 
(61). Results by Copeland et al. (13) showed that during a pathogen challenge in humans, the 
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change in BP and temperature plays a vital role in HR modulation. Septic patients typically develop 
a high fever, low BP and high HR (40). Considering this evidence, we hypothesize that changes in 
temperature and pain perception observed in humans contribute to the fluctuations in HR and BP 
following an endotoxin challenge.  
  The objective of this study is to develop a mathematical model to understand the impact 
of variations in human inflammatory markers on thermal, pain, and hemodynamic responses. We 
hypothesize that LPS-induced inflammation causes fever, leading to higher HR via decreased 
parasympathetic activity and changes in BP-HR interactions. In addition, we hypothesize that 
inflammation lowers the threshold for pain perception and stimulates NO synthesis. Finally, we 
hypothesize that pain and NO have opposing effects on BP. More specifically, a reduced pain 
tolerance increases BP through increased vascular resistance, and an increase in NO leads to a 
decrease in BP through vasodilation.  
To test these interactions, we expand upon our previous dynamic model for a systemic 
inflammatory reaction to LPS (7) by adding pathways for changes in temperature, pain perception, 
NO, HR, and BP. The model is fit to patient data from two independent clinical studies (13, 31). 
We further perform simulation studies of the model’s ability to capture the effects of common 
treatments, such as antibiotics, antipyretics, and vasopressors. 
 
Materials and Methods 
Data and Experimental Design 
Study Subjects 
Copeland et al. (13) administered a bolus dose of LPS to 10 human subjects. The participant group 
included male and female healthy adult volunteers aged 18 to 40 years. Exclusion criteria for 
participation included chronic disease history, e.g. cancer, rheumatoid arthritis, heart disease, and 
hypertension, or history of abnormalities affecting the immune system, e.g. the liver, kidneys, 
endocrine system, or neural system. This study was approved by the Institutional Review Board 
of UMDNJ-Robert Wood Johnson Medical School, all subjects gave written consent to participate. 
The study by Janum et al.  (31) included 20 healthy male adults ages 18 to 35 years, who received 
LPS. Exclusion criteria include smoking, obesity, daily intake of medication, and splenectomy. 
The Regional Committee on Health Research Ethics and the Regional Data Monitoring Board 
approved the investigation protocol, and all participants gave written consent to participate in the 
study.  
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Experimental Protocol 
Both studies followed a similar experimental protocol administering a 2 ng/kg dose of LPS derived 
from Escherichia coli intravenously and measuring the systemic inflammatory response, body 
temperature, HR, and BP.  Copeland et al. (13) assessed participants over 9 hours post-injection, 
while Janum et al. (31) assessed subjects 2 hours before and 6 hours after endotoxin administration. 
The Janum study applied a heat stimulus to the non-dominant thigh at varying temperatures (45, 
46, 47, 48° C) for 5 seconds followed by a period of 32° C to evaluate pain perception. Subjects 
were asked to rate each heat stimulus on a scale from 0 (no pain) to 10 (worst imaginable pain). 
Pain perception was measured using an algometer in which pressure was applied manually at 
increasing kPa. When participants indicated that their pain threshold was reached, the algometer 
value was recorded.  
 In each study, blood samples were collected to measure plasma levels of pro- (TNF-𝛼, IL-6, 
and IL-8) and anti-inflammatory (IL-10) cytokines. Both studies recorded systolic BP and 
temperature at discrete time points; standard BP was measured hourly with a BP cuff on the upper 
arm. The Copeland study measured HR at discrete time points, while Janum et al. (31) measured 
HR continuously throughout the 6-hour interval. Fig. 1 shows the detailed experimental protocol 
for each study.  In our previous study (7) modeling the inflammatory response using the data by 
Janum et al. (31), results are reported as the mean ± standard error of the mean (SEM) for each 
subject. The data extracted from the Copeland et al. study were reported as the average over the 
population.  To compare the response from the two studies we validated model predictions against 
the population average response for each study. Moreover, to predict proper cytokine decay 
synthetic data was added to the Janum et al. (31) data at 𝑡	 = 	7 and 8 hours. Finally, to achieve 
data format consistency for BP and HR between the two studies, we sampled HR and BP 
measurements at the same time-points. 
 
FIG.  1 – DATA DESCRIPTION 
 
Mathematical Model Development 
Our mathematical model (shown in Fig. 2) includes three sub-models of 1) the inflammatory 
response to endotoxin, 2) the effect on temperature, pain perception, and nitric oxide, and 3) their 
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effect on the cardiovascular system. Below we describe each component and their 
interdependencies. 
 
FIG.  2 – FEEDBACK DIAGRAM FOR HUMAN RESPONSE TO LPS 
 
Part I: The inflammatory response to an endotoxin challenge 
Monocytes and macrophages use cytokine signaling to communicate in response to a pathogen 
and are an essential part of innate immunity.  Bone marrow stem cells differentiate into monocytes 
and move into the bloodstream. From here they enter the connective tissue matrix where they 
differentiate into macrophages, which interact with the cytokines (44). Monocytes and 
macrophages are normally at rest, but with a bacterial stimulus (e.g. from LPS) the number of 
macrophages increases by several orders of magnitude.  
 Cytokines are potent signaling molecules that regulate many processes essential to immunity 
and inflammation. In (7), we constructed a classic kinetic model of the systemic inflammatory 
response to an endotoxin challenge, incorporating signaling pathways illustrated in Fig. 3 
(equations are given in the Appendix). We extend this model to include thermal, pain, nitric oxide, 
and hemodynamic models and calibrate it to inflammatory mediator data from the studies  by 
Janum et al. (31) and Copeland et al. (13). 
 
FIG.  3 – INTERACTIONS AMONG IMMUNE COMPONENTS 
 
Part II: The thermal, pain and nitric oxide response 
Thermal effects. The binding of LPS to receptors on macrophages and other immune cells 
stimulates the production of pyrogenic (fever-inducing) cytokines IL-6, TNF-𝛼, and IL-1𝛽, which 
act to induce and maintain fever. These pyrogens stimulate afferent vagal nerves terminating in 
the brain, and this relays information to the hypothalamus about the ongoing inflammation and 
triggers the release of prostaglandins. Prostaglandins act on neurons in the preoptic nucleus of the 
hypothalamus, which is the area responsible for temperature regulation (12, 36). TNF-𝛼 is a potent 
pyrogenic cytokine, and it is one of the main cytokines implicated in septic shock. IL-6 has recently 
been shown to be necessary to sustain fever (16, 24). Conversely, IL-10 has antipyretic effects, 
lowering temperature (12, 43). 
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 To account for this feedback, we introduce temperature regulation modeled as a function of 
TNF-𝛼 and IL-6, which upregulate temperature, and IL-10, which counteracts these effects. 
Temperature is modeled as  𝑑Temp𝑑𝑡 = 1𝜏0 (−Temp + 𝑇5 + 𝑘7(𝑇8 − 𝑇5)(𝑘7:;<𝐻7>(TNF − 𝑤:;<) +𝑘7B𝐻7>(IL6 − 𝑤FGB)−𝑘70H(1 − 𝐻7I(IL10 − 𝑤FG0H))), (3) 
where Temp is temperature,  𝑇5 and 𝑇8 are the respective baseline and maximum temperatures, 
and 𝜏0, 𝑘7, 𝑘7:;<, 𝑘7B, 𝑘70H are rate constants. The baseline values of the cytokines are given by 𝑤L, for 𝑋 ∈ {TNF-𝛼, IL6, IL10}. The up- and down-regulation of Y by X is described by the 
equations 𝐻R>(𝑋) = LSTUVS WLS and 𝐻RI(𝑋) = TUVSTUVS WLS, respectively. The half-saturation is given by 𝜂RL and the exponent ℎ regulates the steepness of the Hill function. 
 While we recognize the importance of IL-1𝛽 in the thermal response, we refrain from 
including it in the temperature equation because this cytokine was not measured in the clinical 
studies from which data was obtained. 
 
Pain Threshold (PT). Sensory neurons at the site of infection are stimulated in the presence of 
inflammation and alter signaling to the CNS through vagal afferent fibers (35).  Nociceptors are 
essential mediators of pain perception (45) and have nerve endings terminating near macrophages 
and other immune cells. Nociceptors express receptors for cytokines such as TNF-𝛼 and IL-6 (8), 
but they can also be activated by bacteria directly. Previous studies (2, 31, 63) show that there is a 
dose-dependent relationship between pain perception and inflammation. We model the threshold 
for perception of pain as 𝑑PT𝑑𝑡 =−𝑘[:\𝐸	PT + 𝑘[:(𝑃𝑇5 − PT), (4) 
where 𝑘_7\ and 𝑘_7 are rate constants and  𝑃𝑇5 is the baseline pain threshold. Upon injection, the 
endotoxin (E) decreases exponentially, resulting in a decrease in the pain perception threshold 
(59). As the body clears endotoxin, the pain perception threshold returns to baseline. 
 
Nitric Oxide (NO). The endothelium cells lining the blood vessels uses nitric oxide (NO) signaling 
to interact with nearby smooth muscle cells, which relax with increased release of NO (37). NO 
has direct and indirect microbial effects including inhibition of pathogen proliferation (3, 4, 58). 
As part of the inflammation pathway, upon signaling from TLRs or inflammatory cytokines, 
Inflammatory-thermal- pain-cardiovascular response to a pathogen challenge 
 
 10 
macrophages produce inducible nitric oxide synthase (iNOS) which affects their phenotype and 
leads to the production of NO (39). TNF-𝛼 upregulates the NO production (51) and IL-10 
downregulates its synthesis (9, 25). We model cytokine-mediated NO dynamics as  𝑑𝑁𝑑𝑡 =𝑘a8𝑀c d TNF(t − κ)ghijkTNF(t − κ)ghijk + 𝜂a:;<ghijkld 𝜂a0HghmnIL10(t − κ)ghmn + 𝜂a0Hghmnl − 𝑘a𝑁. (5) 
In this equation 𝜅 represents the delay in activation/inhibition of NO from TNF-𝛼 and IL-10,  𝑘a8 
and  𝑘a are rate constants, and  𝜂a:;<, 𝜂a0H, ℎa:;<,	and ℎa0H are Hill function parameters 
determining the half-saturation value and steepness of the response. 
 
Part III: Impact of the immune response on cardiovascular dynamics 
The cardiovascular system is continually modified to maintain homeostasis (ensuring adequate 
oxygen perfusion at stable resting BP). The body maintains this state via the autonomic control 
system regulating vascular compliance, resistance, and cardiac contractility and HR. The 
baroreflex branch of the autonomic control system consists of parasympathetic and sympathetic 
signaling primarily responding to changes in BP. The vagal nerve is the primary pathway for the 
parasympathetic signaling. An increase in parasympathetic signaling leads to a decrease in HR 
(62).  This response is caused by release of acetylcholine primarily at the level of the sinoatrial 
node. Preganglionic sympathetic nerve fibers travel through the spinal cord synapses with the 
postganglionic fibers and thus transmit the sympathetic signals, stimulating the release of 
noradrenaline, which causes smooth-muscle contraction, increasing the peripheral vascular 
resistance and decreasing the compliance of the vascular wall.  The baroreflex response to changes 
in BP acts within seconds to minutes, but basal activity in both efferent pathways (parasympathetic 
and sympathetic) are present even in the absence of a stimulus (change in BP). We hypothesize 
that the basal activity level may be modulated by several factors including fever and pain 
perception (21, 32). In addition to neural response, the vascular system is also controlled locally, 
e.g., in response to changes in NO, which is a potent vasodilator and through release of 
catecholamines form the adrenal medulla. To model this feedback, we develop a simple 
cardiovascular model coupled with control for modulating HR and peripheral vascular resistance, 
impacting prediction of BP.   
 
Cardiovascular Model  
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Due to significant BP and HR changes taking place over the course of hours, the current model 
does not account for respiratory dynamics. Therefore, we limit the cardiovascular model to the 
systemic circulation, which we model as a series of compliance (C) and resistance (R) elements 
using an electric circuit analogy. Our model (shown in Fig. 4) consists of four compliance 
compartments representing the large and small arteries and veins. Three resistance elements 
separate these compartments, including the resistance provided by the systemic organs and the 
pressure gradient between the large and small arteries and veins. The model is non-pulsatile since 
the relevant timescale for all model variables is hours, i.e. the pumping of the heart is not explicitly 
incorporated (65).  
 The predicted variables are flow (𝑞	𝑚𝐿/𝑠), volume (𝑉	𝑚𝐿), and pressure (𝑝	𝑚𝑚𝐻𝑔). The 
model is formulated using four differential equations describing conservation of volume via 𝑑𝑉y𝑑𝑡 = 𝑞yz −  𝑞{|}, (6) 
where 𝑞yz is flow entering the compartment, and 𝑞{|} is flow leaving the compartment. Between 
two compartments, flow is related to pressure via Ohm’s law given by  𝑞y=  𝑝{|} −  𝑝yz 𝑅y , (7) 
where 𝑝yz	and	𝑝{|} (mmHg) denote the pressure in the two surrounding compartments and 𝑅y 
(mmHg s/mL) is the resistance to flow.  
 Finally, for each compartment, pressure (𝑝) is related to volume (𝑉) via a pressure/volume 
relation  𝑝 − 𝑝}y = 𝐸(𝑉 − 𝑉|z), (8) 
where 𝑝}y (mmHg) is the tissue pressure, 𝐸	is the elastance, and 𝑉|z is the unstressed volume. We 
drive the cardiovascular model by a “non-pulsatile heart” tracking stroke volume 𝑉} via  𝑄 ≈ 𝐻𝑉}, (9) 
where 𝐻 (beats/min) is the HR, and 𝑄 (mL/s) is the cardiac output. 𝑉}, the volume of blood the 
heart pumps out during one beat, is computed by 𝑉} = 𝑉\I − 𝑉\ = −𝑝𝐸8 − 𝑝𝐸, (10) 
where 𝑉\I is the end-diastolic volume in the heart, 𝑉\ is the end-systolic volume, 𝑝 is pressure 
in the large arteries, 𝑝 is pressure is pressure in the large veins, and 𝐸8 and 𝐸 are the maximum 
and minimum elastance, respectively (1). The Appendix gives a complete list of model equations. 
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 FIG.  4 – CARDIOVASCULAR MODEL 
 
Cardiovascular Control Model. As noted earlier, the cardiovascular control system modulates 
several vascular parameters including peripheral vascular resistance (𝑅), cardiac contractility 
(here represented by 𝐸 and 𝐸8, vascular compliance (𝐶), and heart rate (𝐻).  Given the lack of 
pulsatilility in the model and data, we focus on describing regulation of vascular resistance and 
heart rate. In this system, vascular resistance (𝑅), on the timescale studied here, is primarily 
controlled by pain via sympathetic stimulation, which up-regulates 𝑅, and nitric oxide which 
down-regulates 𝑅.	In response to LPS, the pain perception threshold decreases, upregulating the 
peripheral vascular resistance between the small arteries and veins via sympathetic stimulation. 
Resistance is downregulated by NO. To capture these effects, we model the peripheral vascular 
resistance as 𝑑𝑅𝑑𝑡 =𝑘_7 ΓΓ + 𝜂_7 − 𝑘a𝑁 − 𝑘(𝑅 − 𝑅5), (11) 
where Γ = _7}  is the rate of change of the pain perception threshold and 𝑅5 is the baseline 
peripheral vascular resistance (before the LPS injection) in the absence of pain and nitric oxide 
(Γ = 0 and	𝑁 = 0). The rate constants are given by 𝑘_7, 𝑘a, and 𝑘a. The half-saturation value 
of the Hill function is given by 𝜂_7 Upon administration of endotoxin, the pain threshold 
decreases, resulting in an increase in Γ and consequently 𝑅. As LPS decays and PT returns to its 
baseline value, Γ	approaches zero. NO begins to rise two to four hours after the initial 
inflammatory response, causing 𝑅 to decrease. 
 The changes in peripheral vascular resistance lead to changes in BP. Elevated vascular 
resistance, brought about by stimulation of the sympathetic system in response to increased pain 
perception, leads to a rise in BP. On the other hand, a high NO concentration notably lowers 
resistance through vasodilation, which can lead to an excessive drop in BP (50).  
 Due to activation of the baroreflex, the increase in BP leads to a decrease in HR, while during 
hypotension, the excessive BP drop causes an increase in HR. Also, with fever induction as a 
consequence of the pyrogens released by monocytes, the CNS decreases basal vagal tone, which 
increases HR (32). To predict these responses in HR dynamics, we model HR as follows 
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𝑑𝐻𝑑𝑡 = −𝐻 + 𝑘(𝐻8 − 𝐻5)𝐻>(Temp − 𝑇5)𝑓(𝐵𝑃, 𝐵𝑃5) + 𝐻5𝜏 , (18) 
where 𝑓(𝐵𝑃, 𝐵𝑃5) = 𝐻>(𝐵𝑃5 − 𝐵𝑃)	, if	𝐵𝑃 ≤ 100	mmHg𝐻I(𝐵𝑃 − 𝐵𝑃5), if	𝐵𝑃 > 100	mmHg. 
We prescribe a switching systolic BP level of 100 mmHg since the hypotension cutoff value can 
range between 90 mmHg and 117 mmHg, depending on age (42). HR will increase in response to 
hypotension, which is supported by the observation that when BP is low HR rises to compensate 
for reduced cardiac preload resulting from vascular dilation (23). Otherwise, BP would act to lower 
HR. Both effects depend on temperature elevated above its baseline level. In sum, we are proposing 
that BP impacts HR on the time scale of hours during infections, but not in the absence of fever 
under normal circumstances. 
 
Model Summary 
The model described above can be written in the following form 𝑑𝑥𝑑𝑡 = 𝑓(𝑥, 𝑡; 	𝜃), (13) 
where 𝑥 = 𝑥yz , 𝑥¡¢, 𝑥£¤ is the vector of model states (𝑥 ∈ 𝑅H)	and 𝜃 = 	𝜃yz , 𝜃¡¢, 𝜃£¤ is the 
vector of parameters (𝜃 ∈ 𝑅¥¥). The subscripts inf, reg, and cv represent the inflammatory, 
regulatory, and cardiovascular sub-models, respectively. That is,  𝑥yz  = {𝐸,𝑀,𝑀c, TNF, IL6, IL8, IL10}	𝑥¡¢ = {𝑇emp, PT, NO, 𝑅, 𝐻} 𝑥£ = {𝑉, 𝑉, 𝑉{, 𝑉{, 𝑝, 𝑝, 𝑝, 𝑝}. (14) 
The elements of 𝜃 are: 𝜃yz  = {𝑘\, 𝑘8, 𝑘8:;<, 𝑘8, 𝑘8c,𝑀¨, 𝜂8\, ℎ8\, 𝜂8:;<, ℎ8:;<, 𝜂80H, ℎ80H,	 𝑘:;<8, 𝑘:;<, 𝜂:;<B, ℎ:;<B, 𝜂:;<0H, ℎ:;<0H, 𝑤:;<, 𝑘B8, 𝑘B, 𝑘B:;<, 𝜂B:;<, ℎB:;<, 𝜂BB, ℎBB, 𝜂B0H, ℎB0H, 𝑤FGB, 𝑘¥8, 𝑘¥, 𝑘¥:;<, 𝜂¥:;<, ℎ¥:;<, 𝜂¥0H, ℎ¥0H, 𝑤FG¥, 𝑘0H8, 𝑘0H, 𝑘0HB, 𝜂0HB, ℎ0HB, 𝑤FG0H} 𝜃¡¢ = {𝜏0, 𝑘7, 𝑘7:;<, 𝑘7B, 𝑘70H, 𝑇5, 𝑇8, 𝜂7:;<, 𝜂7B, 𝜂70H, ℎ7:;<, ℎ7B, ℎ70H, 𝑘[:\, 𝑘[:, 𝑃𝑇5, 
(15) 
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𝑘a8, 𝑘a, 𝜂a:;<, ℎa:;<, 𝜂a0H, ℎa0H, 𝑘_7, 𝑘a, 𝑘, 𝜂_7, 𝑅5 𝜏, 𝑘, 𝐻5, 𝐻8, 𝐵𝑃5, 𝜂7, ℎ7, 𝜂_, ℎ_} 𝜃£ = {𝑅, 𝑅, 𝐸, 𝐸, 𝐸, 𝐸, 𝑉}{©¡, 𝐸, 𝐸8}. 
Table 1 lists all model parameters along with units and a description of their function. 
 
Nominal Parameter Values 
As described above, the model is comprised of three sub-models, namely the inflammatory, 
regulatory, and cardiovascular models. For each clinical study, we select a nominal parameter set 
which generates model dynamics that qualitatively align with the data trends.  
 Inflammatory sub-model: For Janum et al., parameter values for the inflammatory sub-model 
were taken from (7). For Copeland et al., parameters were adapted from (7), with several values 
being adjusted to achieve a better alignment between the model outputs and the data. Among the 
parameters that differ between the studies are the baseline levels of cytokines, the IL-6 synthesis 
in response to TNF-𝛼, the rate at which TNF-𝛼 activates monocytes, and the monocyte production 
rate of TNF-𝛼 and IL-6. See Table 2 for a complete list of the parameters different between the 
two studies. 
 Cardiovascular sub-model: For both studies we calculate the cardiovascular parameters as 
described in (6). The values for elastance in each compartment (𝐶y) and minimum and maximum 
elastance (𝐸 and 𝐸8), presented in Table 2, are computed with the following equations: 𝐸y = 𝑝y𝑉},y, 𝑉},y = 𝑉y − 𝑉|z,y, 𝐸 = 𝑝𝑉\I,	 𝐸8 = 𝑝𝑉\, (16) 
where 𝑉},y is the stressed volume and 𝑉|z is the unstressed volume in compartment 𝑖. The end-
diastolic and end-systolic volume in the heart are given by 𝑉\I = 142 − 𝑉|z, 𝑉\ = 47 − 𝑉|z, 
with  𝑉|z = 10 (6).  
 The calculation of 𝑉},y assumes that systemic volume is 85% of total blood volume, while 
the arterial and venous volumes are 20% and 80% of systemic volume, respectively (6). Total 
blood volume (𝑉}{}) is a function of body surface area (BSA) and takes gender into account. They 
are given by 𝑉°±°,²³´µ¶³ = 1000	(3.47BSA − 1.954) 
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𝑉°±°,´µ¶³ = 1000	(3.29BSA − 1.229) 
𝐵𝑆𝐴 = ¼ ℎ	𝑤3600	, 
where ℎ (cm) is height and 𝑤 (kg) is weight (6).  
 Regulatory sub-model: For both studies, the parameters in the regulatory sub-system are 
adapted from (6) and adjusted where necessary to align with the data (Table 2). We set the 
parameters representing the baseline levels of temperature, HR, and BP (𝑇5, 𝐻5, and 𝐵𝑃5, 
respectively) to the initial points in the data sets, that is, the measurements at 𝑡 = 0. The equations 
for temperature and HR also have maximum level parameters (𝑇8 and 𝐻8, respectively) which 
are informed by the literature. 𝑇8 is 39.5° C, the cutoff for life-threatening hyperthermia (48), and 𝐻8 is 207 (beats/min) (20). In addition, the delay κ in the NO equation is chosen to ensure that an 
increase in NO is observed two to four hours after LPS administration (34).  
 
Parameter Estimation 
We fit the model to the measurements available for immune mediators, temperature, BP and HR, 
by minimizing the least squares error between the model output and the data averaged over the 
population of healthy subjects in each study. The least squares error 𝐽 is given by  𝐽 = 𝑟7𝑟, where	𝑟 = 1√𝑁 𝑌 ±Ä³¶ − 𝑌Äµ°µ𝑌Äµ°µÅÅÅÅÅÅ , (17) 
where 𝑌 ±Ä³¶ and 𝑌Äµ°µ are the model output and measured data, respectively. 𝑌Äµ°µÅÅÅÅÅÅ is the mean of 
the data, and 𝑁 is the total number of data points (38). For this study, we minimize 𝐽	using the 
built-in optimization routine fminsearch in MATLAB.  
 To determine which parameters to estimate, we used sensitivity analysis and subset selection 
for each sub-system of our mathematical model. Sensitivity analysis was carried out using a local 
derivative-based approach where parameters are varied one at a time to determine the sensitivity 
of the model output to its parameters. If small perturbations in a parameter result in significant 
changes in the output, the parameter is sensitive. If not, then the parameter is insensitive. The 
relative sensitivity was computed with a forward difference approximation, as described in (33) 
and ranked sensitivities were computed using the two-norm averaging time-varying sensitivities 
to find a group of sensitive parameters for each sub-model. 
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 After a set of sensitive parameters was identified, we used subset selection by the correlation 
method outlined in (41) to determine which of the sensitive parameters were identifiable. A 
parameter is unidentifiable if it has a linear dependence on the values of other parameters. The 
parameters we estimated (given in Table 3) were ones that were both sensitive and identifiable. A 
detailed presentation of the sensitivity analysis and subset selection is given in (6) gives a detailed 
presentation of the sensitivity analysis and subset selection. Since the sensitivity matrix is 
evaluated at the nominal parameter values, this analysis is only valid in a neighborhood around the 
nominal values. Therefore, we repeated the subset selection at the optimized parameters to ensure 
that the estimated parameters are still identifiable. 
 
Therapeutic Interventions 
We use the physiological model to carry out an in-silico exploration of several therapeutic 
strategies for mitigating the harmful effects of an infection.  Symptoms of an infection include 
elevated temperature, and in later stages, decreased blood pressure (22).  Antibiotics are used to 
clear the pathogen from the body.  Antipyretics help to decrease body temperature, and 
vasopressors increase organ bed resistance, leading to an increase in BP. In this light, our in-silico 
experiments focus on interventions with antibiotics, antipyretics, vasopressors, and a combination 
treatment which incorporates all three. 
 To model an infection state, we let the endotoxin to remain constant over a 12-hour time 
window. This approach simulates the situation when the body is not capable of clearing the 
pathogen from the bloodstream on its own (50). This causes the systolic BP to fall to a hypotensive 
level (below 90 mmHg) (42, 60). This state only arises after a prolonged period of inflammation 
not examined in the Copeland and Janum studies, who only considered the response to a bolus 
LPS injection resulting in controlled inflammation where systolic BP rises slightly in response to 
endotoxin and then decreases back toward the nominal level. By adding the simulation of infection, 
we show that our model can account for the physiological response during controlled inflammation 
as well as for the case of hypotension.  
 We captured the action of antibiotics by increasing the decay rate of LPS (𝑘\). The time 
frame for initiating antibiotic administration considers that medical intervention is not used before 
the infection has resulted in a significant rise in temperature. A commonly used indicator is fever, 
and the peak in body temperature occurs at about 4 hours. We modeled antipyretics by changing 
the PT and temperature dynamics, allowing them to reach baseline levels faster, and vasopressors 
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by increasing the rate at which resistance approaches its baseline level, which in turn affects BP. 
Lastly, we look at a combined therapeutic protocol, that targets LPS, pain and fever, and resistance 
simultaneously. The Appendix gives a detailed description of the implementation of these 
therapeutic interventions. 
 
Results  
Parameter Estimation 
We apply the physiological mathematical model to the two datasets. Fig. 5A shows model 
predictions together with the observed average behavior of immune mediators among human 
subjects exposed to endotoxin in the Copeland et al. study. Fig. 5C presents the comparison with 
the Janum et al. investigation. The pro-inflammatory cytokines TNF-𝛼, IL-6, and IL-8 start to 
increase about 1 hour following the LPS injection, reach a peak concentration at about 2 hours and 
return toward their baseline levels at about 4 hours. IL-10, the mediator with immunosuppressive 
activity, begins to rise shortly after the other cytokines, close to 1.5 hours post endotoxin 
administration. IL-10 reaches its maximum between 2.5 and 3 hours and causes the pro-
inflammatory cytokines to decrease. 
 Figs. 5B and 5D present the comparison between the measured and model-predicted 
response in body temperature, HR, and BP following the LPS challenge. Fig. 5B is the model fit 
to the Copeland et al. data, and Fig. 5D to the Janum et al. data. The inflammatory cascade caused 
by endotoxin leads to a fever. The elevated TNF-𝛼 and IL-6 concentrations result in core body 
temperature significantly higher than the baseline between 3.5 and 4 hours. Subsequently, 
temperature causes a notable increase in HR within the same time frame. Also, the fever influences 
the interaction between BP and HR. LPS exposure leads to an increase in BP at approximately 1.5 
hours, which acts to decrease HR, but the temperature effect dominates the dynamics, and HR 
remains elevated above baseline.  
 After fitting the model to data, we discovered that temperature alone is not enough to explain 
the HR dynamics. We observed that elevated temperature increases HR, but the subsiding of fever 
did not lead to a decrease in HR as seen in the data (Fig. 6). This indicates that, apart from 
temperature, there must be another HR control mechanism causing the restoration of homeostasis, 
and our findings suggest that BP could be this control mechanism. 
 We first tested an equation structure for the HR variable, where temperature and BP were 
accounted for as independent effects, by adding their contributions. The results (Fig. 6) reveal that 
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this model does not fully capture the dynamics of the observed HR response. This led us to 
hypothesize that the effects of BP on HR, on the time scale of hours, are temperature-dependent, 
and the model fits to the data confirm this hypothesis.  
 
FIG.  5 – MODEL FITS TO DATA 
 
FIG.  6 – TEMP ALONE & INDEPENDENT TEMP AND BP EFFECTS  
 
Therapeutic Interventions 
We further probe the validity of the mathematical model by using it to predict responses to 
treatments. We examine the model predictions in the case of a sustained inflammatory event 
causing an infection as well as the effects of different treatment alternatives, including antibiotics, 
antipyretics, vasopressors, and a therapy combining all three medications. Results of these 
simulations are summarized in Figs. 7 and 8. 
 
Infection State 
Infection can be described by a sustained inflammatory event where the immune cells are 
ineffective at clearing it from the bloodstream. The physiological response to an untreated 
infection includes a significant increase in HR and a drop in BP, which in severe cases fall to a 
hypotensive level (defined as a systolic BP at rest below 100 mmHg). 
 An infection dramatically decreases the number of resting monocytes, leading to a higher 
level of activated monocytes, compared to the case of a controlled inflammatory response (Fig. 
S1). The pro-inflammatory cytokines peak earlier in the presence of an infection when compared 
to baseline. However, they reach similar maximum concentrations. The anti-inflammatory 
cytokine IL-10 reaches a notably higher level, and this translates into a slightly lower peak in 
temperature since IL-10 suppresses the thermal response. The temperature does not return to its 
nominal level as it does in a normal inflammatory response (Fig. 7) due to the slow decay of 
pyrogens. 
 The sustained presence of LPS during infection also causes a significant drop in the pain 
threshold. NO concentrations are higher due to release from the increased number of activated 
monocytes (Fig. 7). These response indicators have opposite effects on resistance. The initial 
change in PT is more dramatic than the increase in NO, resulting in a more significant increase in 
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resistance when compared to the response in the absence of infection. However, after 4 hours, the 
rate of PT decline is slow, while NO is still sufficiently elevated. This results in a decreasing 
resistance. The rise in resistance leads to a higher BP than in the case of a normal inflammatory 
response, including the maximum value. As the resistance drops, a notable decrease occurs in BP, 
bringing it in a hypotensive range, which persists.  
 In response to an infection, our simulation results (Fig. 7) show a significant increase in HR 
as a temperature rises. The maximum HR reached is like that in a normal inflammatory response. 
As the thermal response subsides, HR begins to decrease with further downregulation from BP. 
However, as BP decreases into the hypotensive range, HR increases again to compensate for 
reduced blood circulation (23). 
 
Antibiotics  
In this scenario, the bacterial toxin has a sustained presence for 4 hours, and then antibiotics are 
administered to accelerate its clearance from the bloodstream. Antibiotics are a standard treatment 
used to fight bacterial pathogens (22, 50).  Intervening with antibiotics prompts a slow recovery in 
the PT and helps to bring temperature and HR down toward their nominal levels. On the other 
hand, BP increases slightly, but there is no significant improvement toward recovery from the 
hypotensive range (Fig. 7). This is due to the introduction of antibiotics after the number of 
activated monocytes reaches a peak. The large cell population results in elevated NO, which has a 
stronger influence on the cardiovascular system compared to the change in PT.  
 
Antipyretics 
Fever is usually a part of the body’s response to infection as well as an element in the inflammation 
from other causes. In the intensive care unit, about 70% of patients experience fever (11). In 
addition, surgical procedures are associated with a noticeable increase in body temperature (19). 
Antipyretic medication is a commonly used therapeutic approach for managing fever and pain to 
lessen the strain on the cardiovascular system and improve patient recuperation outcomes (53). As 
with antibiotics, introducing antipyretics into the model leads to recovery in HR. On the other 
hand, there is a moderate improvement in BP but only for a short time following antipyretic 
administration (Fig. 7). Then, BP falls to the hypotensive rage and does not recover. Also, the BP 
level decreases more compared to the case of antibiotic administration. This is due to NO being 
sufficiently elevated and exerting a stronger effect on peripheral vascular resistance than the 
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change in PT. As antipyretics do not directly affect endotoxin levels, the inflammatory mediators 
and NO remain as in the infectious state. In addition, the decrease in HR causes further drop in BP 
due to lower cardiac output.  
 
Vasopressors 
The inflammatory response to an infection results in increased nitric oxide production (50), which 
leads to a significant drop in systemic blood pressures. Vasopressors may be used to elevate these 
pressures to a normal level (22, 49, 50). Like antipyretics, vasopressors do not affect endotoxin 
levels, resulting in no change in inflammatory mediators, NO, PT, or temperature. The action of 
vasopressors increases resistance, which translates into recuperation of systolic BP to its nominal 
level. Despite this, HR remains abnormally elevated (Fig. 7).  
 
Multimodal Treatment 
The multimodal therapeutic strategy simultaneously targeting toxin clearance, pain and fever, as 
well as low resistance, renders the best outcome since it brings about the alleviation of pain as well 
as recovery of normal body temperature, HR, and BP (Fig. 8).  
 
FIG.  7 – ANTIBIOTICS, ANTIPYRETICS, AND VASOPRESSORS  
 
FIG.  8 – MULTIMODAL TREATMENT 
Discussion 
The model successfully captures the immuno-pain-thermal-cardiovascular behavior and their 
interactions in two clinical studies of healthy adults under an LPS challenge. In response to an 
inflammatory reaction against a bacterial toxin, the model shows elevation of body temperature to 
a febrile level that we hypothesize leads to a notable rise in HR. These results are consistent with 
the data, Foteinou et al. (18) and our previous observations (7) that inflammation leads to an 
increased HR. While the study by Foteinou et al. hypothesized that the HR increase resulted from 
amplified efferent sympathetic activity and diminished parasympathetic activity, the study did not 
elucidate the role of temperature. Additionally, the study only indirectly accounted for the pain 
response through the inclusion of a sympathetic activity variable.  
 Inclusion of the thermal component into the current model illustrates the immune system’s 
impact on HR via the febrile response. The release of inflammatory cytokines, in particular, IL-6 
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and TNF, raises core body temperature (61). Our findings suggest that the thermal response is an 
integral part of the interaction between BP and HR during an infection, on a time scale of hours, 
providing support for our hypothesis that during fever while BP is in a normotensive range, BP 
acts to lower HR, and when the temperature is at its baseline level, no dramatic HR fluctuations 
are observed. 
 Our model directly addresses the role of the pain pathway in the human response to 
endotoxin. Using data and observations from Janum et al. (31) our model reveals that the body’s 
pain threshold diminishes during an endotoxin challenge. In addition, our investigation shows that 
the pain response is linked to cardiovascular dynamics and leads to a slight increase in BP in the 
early stages of the inflammatory reaction.  
 
Therapeutic Interventions 
The onset of an infection initiates a cascade of physiologic reactions acting at multiple timescales, 
complicating critical care for the patient. This study performs a simulation-based treatment 
investigation to predict the impact of several interventions commonly used in the clinical 
management of infection.  We simulate an infection by keeping the endotoxin level constant, 
simulating the body’s inability to effectively remove the endotoxin (50). The model predicts 
detrimental pathophysiological effects of sustained LPS presence including fever, increased 
sensitivity to pain, hypotension, and elevated HR. These results are consistent with the symptoms 
observed in sepsis (40). However, it should be noted that in septic patients who have a Gram-
negative infection, the LPS level is much higher than the 2 ng/kg dose used in the clinical studies. 
 Antibiotics are typically used to treat bacterial infections. In the management of sepsis, 
broad-spectrum antibiotics are given to patients intravenously to combat the spreading pathogen 
and reduce the bacterial endotoxin level (22, 50). The simulation results from our model 
demonstrate that antibiotics lead to fever reduction, pain relief, and HR normalization, but not a 
notable improvement in BP.  
 Antipyretics are used to reduce core body temperature and pain (46). This treatment, 
however, does not block the dynamics of inflammatory cytokines (55). According to (46), the 
benefits and drawbacks of such medication are not well understood. Fever may serve an essential 
role in fighting the infection, but it may also negatively impact the cardiovascular system. Our 
findings indicate that while antipyretics favorably affect pain, body temperature, and HR, they are 
unable to reverse hypotension. Vasopressors are an alternative treatment option that targets the 
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cardiovascular system. The simulation analysis illustrates that vasopressors are successful in 
normalizing systolic BP, but they fail to alleviate fever, pain, and reverse abnormally high HR.  
 Uncontrolled infection, which spreads and leads to sepsis, is a multifaceted condition with 
numerous possibilities for treatment, as seen in its pathophysiology and recent treatment guidelines 
(26, 27). Considering this, a multimodal treatment strategy was simulated, where antibiotics, 
antipyretics, and vasopressors are introduced simultaneously into the system. As the model 
captures complex interactions among immune, thermal, pain, and cardiovascular components, the 
goal was to assess how the combined administration of interventions impacts the predicted 
behavior and compares with the outcomes from the individual treatment administrations. Our 
results demonstrate that when combined, antibiotics, antipyretics, and vasopressors affect the 
model variables in essentially the same way as they did independently. Vasopressors act to restore 
normal BP, antipyretics restore PT and temperature, and the HR trends to its baseline value. 
Overall, this in-silico assessment shows that the combination treatment is the most effective way 
to relieve pain and bring about the recovery of normal temperature, HR, and BP.  While these 
results are promising, future work is needed to understand how the medications act either 
synergistically or in competition to counteract an inflammatory event.  
 The data fitting and simulation analysis demonstrates that the model provides a platform to 
explore how specific biological pathways affect predicted cardiovascular outputs. There is an 
advantage in tracking the cardiovascular response through HR and BP since these quantities can 
be measured non-invasively and interpreted within minutes, allowing for a much quicker patient 
assessment compared to blood sampling to determine plasma levels of pro-inflammatory 
cytokines.  
 
Limitations and future work 
A limitation of our model is that it is calibrated over a short time course dictated by the time scale 
of the two endotoxin clinical studies, of duration 9 hours and 6 hours. This makes it difficult to 
assess its ability to track dynamics over days, which is needed to understand the response to an 
infection. Moreover, we only analyze data from a small number of subjects (10 and 20, 
respectively) increasing the uncertainty of model predictions. 
 In addition, there are several simplifying assumptions within the model. First, we assume 
that the endotoxin decays at a linear rate and is otherwise uncoupled from the rest of the 
model. This model is appropriate for studying the endotoxin response to a bolus LPS injection, but 
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the model needs additional components to predict the response to treatment. In future studies, we 
will investigate the interactions among activated macrophages, pathogens and fever since there is 
evidence suggesting that aggressive treatment for body temperature higher than 38.5°C can 
negatively affect the recovery of critically ill patients, decreasing their ability to successfully clear 
infections (53). Furthermore, fever is beneficial in combating pathogens by limiting their 
reproduction, increasing the activity of many classes of antibiotics, and increasing the innate 
immune response (61).   
 Other potential extensions of the model include the investigation of treatments for 
sepsis.  Our preliminary numerical experiments indicate that, qualitatively, antibiotic treatment 
slightly increases BP and lowers HR. Septic shock, a life-threatening condition, results from 
uncontrollable sepsis, and symptoms include low BP and rapid HR (40). Though our model is able 
to obtain accurate fits to the data and predict how an individual will respond to treatment, 
additional work is necessary to incorporate the effect of tissue damage on the inflammatory 
response, as shown in the model by Chow et al. (10).  
 Clinically, there are several evolving phases of infection from early to later stages, including 
sepsis, severe sepsis, and septic shock (22).  These phases differ in several ways, including 
evidence of organ dysfunction and persistent hypotension (22).  Our model currently does not 
distinguish between these phases, as it was developed to investigate dynamics within short time 
scales following an endotoxin challenge.  To extend the model to analyze its response to an 
infection, the model should be solved over longer timescales (days).  
 
Conclusion 
This work develops the first physiological mathematical model that explains the interactions in 
humans among inflammation, body temperature, pain, HR, and BP. The model successfully 
captures the time-course of events and interplays observed during a pathogen challenge in healthy 
individuals reported in two clinical studies. For both studies, the inflammatory response is 
adequately controlled and contained, and the bacterial endotoxin is effectively cleared from the 
bloodstream within 6 to 9 hours. Simulation analysis of therapeutic interventions suggests that an 
untreated, sustained pathogen challenge would bring about abnormally elevated HR and low BP. 
Simulation results show that to remedy these detrimental effects, the most effective approach is to 
administer a multimodal treatment combining antibiotics with antipyretics and vasopressors to 
simultaneously target toxin, pain, fever, and low vascular resistance. 
Inflammatory-thermal- pain-cardiovascular response to a pathogen challenge 
 
 24 
Acknowledgements 
We would like to thank S. Janum, K. Møller, and S. Brix for their contributions to the data 
collection process. 
Grants 
Dobreva and Olufsen were supported in part by NSF–RTG–1246991. Puelz was supported in part 
by the NSF/DMS–RTG–1646339, and Brady was supported by The Jayne Koskinas Ted Giovanis 
Foundation for Health and Policy. Olufsen, Puelz, Larripa, and Brady were also supported by the 
Mathematics Research Communities via an award to the AMS (NSF–DMS–1321794).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inflammatory-thermal- pain-cardiovascular response to a pathogen challenge 
 
 25 
Appendix 
 
Inflammatory Response 
The equations of the inflammatory response are given by 𝑑𝐸𝑑𝑡 = −	𝑘\𝐸. 𝑑𝑀𝑑𝑡 = −𝐻8>(𝐸)(𝑘8 + 𝑘87aÆ𝐻8>(𝑇𝑁𝐹))𝐻8I(𝐼𝐿10)𝑀 + 𝑘8𝑀 1 − 𝑀𝑀¨ 𝑑𝑀c𝑑𝑡  = 𝐻8>(𝐸)(𝑘8 + 𝑘87aÆ𝐻8>(𝑇𝑁𝐹))𝐻8I(𝐼𝐿10)𝑀 − 𝑘8c𝑀c 𝑑𝑇𝑁𝐹𝑑𝑡 = 𝑘7aÆ8𝐻7aÆI (𝐼𝐿6)𝐻7aÆI (𝐼𝐿10)𝑀c − 𝑘7aÆ(𝑇𝑁𝐹 − 𝑤7aÆ) 𝑑𝐼𝐿6𝑑𝑡 = (𝑘B8 + 𝑘B7aÆ𝐻ÉÊB> (𝑇𝑁𝐹))𝐻ÉÊBI (𝐼𝐿6)𝐻ÉÊBI (𝐼𝐿10)	𝑀c − 𝑘B(𝐼𝐿6 − 𝑤ÉÊB) 𝑑𝐼𝐿8𝑑𝑡 =  (𝑘¥8 + 𝑘¥7aÆ𝐻ÉÊ¥> (𝑇𝑁𝐹))𝐻ÉÊ¥I (𝐼𝐿10)	𝑀c − 𝑘¥(𝐼𝐿8 − 𝑤ÉÊ¥) 𝑑𝐼𝐿10𝑑𝑡 =  (𝑘0H8 + 𝑘0HB𝐻ÉÊ0H> (𝐼𝐿6))	𝑀c − 𝑘0H(𝐼𝐿10 − 𝑤ÉÊ0H), 
(1) 
where the up- and down-regulation of Y by X is modeled using the Hill functions, 𝐻R>(𝑋) =LSTUVS WLS and 𝐻RI(𝑋) = TUVSTUVS WLS, respectively. Full model details can be found in (7). 
 
Cardiovascular Response 
By conservation of volume, the changes in volume in the large and small arteries and veins are 𝑑𝑉𝑑𝑡 = 𝑄 −  𝑞, 𝑑𝑉𝑑𝑡 = 𝑞 −  𝑞, 𝑑𝑉𝑑𝑡 = 𝑞 −  𝑞, 𝑑𝑉𝑑𝑡 = 𝑞 − 𝑄. (2) 
The flow through each compartment is found using Ohm’s law giving  𝑞=  𝑝 −  𝑝 𝑅 ,  𝑞=  𝑝 −  𝑝 𝑅 ,  𝑞=  𝑝 −  𝑝 𝑅 , (3) 
where 𝑅 and 𝑅 are arterial and venous resistances, and  𝑅 is the peripheral vascular resistance. 
 For each cardiovascular compartment, the pressure and volume are related by 𝑝y − 𝑝}y = 𝐸y(𝑉y − 𝑉|z), (4) 
where 𝑉y is the volume of the compartment, 𝑉|z  is the unstressed volume, 𝐸y  is the elastance of 
the compartment, 𝑝y is the pressure in the compartment, and 𝑝}y is the tissue pressure.  
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Therapeutic interventions 
We perform a theoretical therapy study over a 12-hour time window. 
Infection State: To simulate an infection, we assume the amount of endotoxin (𝐸) remains constant 
for 12 hours, i.e. 𝑑𝐸𝑑𝑡 = 0. (5) 
Antibiotics are administered four hours after the onset of the infection to mimic typical action of 
patients seeking help once they experience fever. We hypothesize that antibiotics will increase the 
rate at which the endotoxin clears from the bloodstream and model this as  𝑑𝐸𝑑𝑡 = Ë 0, if	𝑡 ≤ 4−2 ∙ 𝑘\𝐸, if	𝑡 > 4. (6) 
That is, there is a constant, sustained endotoxin presence initially, which begins to decay once the 
antibiotics are introduced at 𝑡 = 4. The rate at which this occurs is set to be twice as fast as the 
endotoxin would decay during an inflammatory event without intervention with an antibiotic. 
 
Antipyretics are also introduced into the model at 𝑡 = 4. We model the effect of antipyretics by 
changing the pain threshold (PT) and the temperature gain (Temp) making them approach their 
baseline values (𝑃𝑇5 and 𝑇5, respectively) at rates which are slightly faster than in the baseline 
simulation. To model this effect, we modify equations for pain perception and temperature as 𝑑PT𝑑𝑡 = Ë−𝑘[:\𝐸	PT + 𝑘[:(𝑃𝑇5 − PT), if	𝑡 ≤ 42 ∙ 𝑘_7(𝑃𝑇5 − PT), if	𝑡 > 4 
𝑑Temp𝑑𝑡 = ⎩⎪⎨
⎪⎧ 1𝜏0 (−Temp + 𝑇5 + 𝑘7(𝑇8 − 𝑇5)(𝑘7:;<𝐻7>(|TNF − 𝑤:;<|)																				+𝑘7B𝐻7>(|IL6 − 𝑤FGB|)−𝑘70H(1 − 𝐻7I(|IL10 − 𝑤FG0H|))), if	𝑡 ≤ 42𝜏0 (−Temp + 𝑇5),																																																																																		if	𝑡 > 4.
 
(7) 
 
Vasopressors are also introduced 4 hours after the infection. Their action leads to an increase in 
peripheral vascular resistance (𝑅). We model this effect by letting the peripheral vascular 
resistance approach its baseline value (𝑅5) more quickly, i.e. 𝑑𝑅𝑑𝑡 = Ò𝑘_7 ΓΓ + 𝜂_7 − 𝑘a𝑁 − 𝑘(𝑅 − 𝑅5), if	𝑡 ≤ 4−2 ∙ 𝑘(𝑅 − 𝑅5), if	𝑡 > 4. (8) 
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Multimodal Treatment also initiated 4 hours after the infection onset combines antibiotics, 
antipyretics, and vasopressors combining the models in (5-8).  
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Tables 
 
Table 1. Descriptions and units of model parameters (exponent (exp); in response to (irt); 
number of cells (noc); temperature (Temp); heart rate (HR); blood pressure (BP); nitric 
oxide (NO); organ bed resistance (𝑹𝒔); pain threshold (PT)). 
 
Par. Description Unit  Par. Description Unit 
Inflammatory Sub-Model 𝒌𝑬 Endotoxin decay rate hr-1  𝒌𝑴𝑹 𝑀 proliferation rate hr-1 𝒌𝑴 Rate that endotoxin activates monocytes hr-1  𝒌𝑴𝑨 
Decay rate of 𝑀c,	TNF-𝛼, IL6, IL8, 
and IL10, 
respectively 
hr-1 
𝒌𝑴𝐓𝐍𝐅 Rate that TNF-𝛼 activates monocytes hr-1  𝒌𝐓𝐍𝐅 𝒌TNF𝑴 𝑀c production rate 
of TNF-𝛼, IL6, IL8, 
and IL10, 
respectively 
pgmL	hr	noc 
 
 𝒌𝟔 𝒌𝟔𝑴  𝒌𝟖 𝒌𝟖𝑴  𝒌𝟏𝟎 𝒌𝟏𝟎𝑴  𝒘𝐓𝐍𝐅  
Baseline TNF-𝛼,	 IL6, IL8, and IL10, 
respectively 
pg/mL 
𝒌𝟔𝐓𝐍𝐅 IL6 and IL8 
synthesis in 
response to TNF-𝛼 pgmL	hr	noc  𝒘𝐈𝐋𝟔 𝒌𝟖𝐓𝐍𝐅  𝒘𝐈𝐋𝟖 𝒌𝟏𝟎𝟔 IL10 synthesis in response to IL6 pgmL	hr	noc  𝒘𝐈𝐋𝟏𝟎 𝜼𝑴𝑬 𝑀c half-max irt endotoxin ng/kg  𝒉𝑴𝑬 Exp. modulating 𝑀c effect on endotoxin - 𝜼𝑴𝐓𝐍𝐅 Half-max of 𝑀c, IL6 
and IL8, resp. 
regulating TNF-𝛼 pg/mL 
 𝒉𝑴𝐓𝐍𝐅 Exp. modulating 𝑀c, IL6 and IL8, 
resp. effect on TNF-𝛼 - 𝜼𝟔𝐓𝐍𝐅  𝒉𝟔𝐓𝐍𝐅 𝜼𝟖𝐓𝐍𝐅  𝒉𝟖𝐓𝐍𝐅 𝜼𝑴𝟏𝟎 Half-max of 𝑀c,	TNF-𝛼, IL6	 and IL8, resp. regulating IL10 pg/mL 
 𝒉𝑴𝟏𝟎 Exp. modulating 𝑀c,	TNF-𝛼, IL6	 and IL8, resp. effect on IL10 - 𝜼𝐓𝐍𝐅𝟏𝟎  𝒉𝐓𝐍𝐅𝟏𝟎 𝜼𝟔𝟏𝟎  𝒉𝟔𝟏𝟎 𝜼𝟖𝟏𝟎  𝒉𝟖𝟏𝟎 𝜼𝐓𝐍𝐅𝟔 Half-max of TNF-𝛼, IL6	 and IL10, resp. 
regulating IL6 pg/mL 
 𝒉𝐓𝐍𝐅𝟔 Exp. modulating TNF-𝛼, IL6	 and IL10, resp. effect on IL6 - 𝜼𝟔𝟔  𝒉𝟔𝟔 𝜼𝟏𝟎𝟔  𝒉𝟏𝟎𝟔 𝑴¨ Max number of monocytes noc     
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Table 1. (cont) 
 
Par. Description Unit  Par. Description Unit 
Cardiovascular Sub-Model 𝑹𝒂 Resistance in 
arteries and veins, 
respectively 
mmHg	minmL   𝑬𝒍𝒂 Elastance of large and small arteries 
and veins, 
respectively 
mmHgmL  𝑹𝒗  𝑬𝒔𝒂 𝑬𝒎 Min and max 
elastance, 
respectively 
mmHgmL   𝑬𝒍𝒗 𝑬𝑴  𝑬𝒔𝒗 
Regulatory Sub-Model 𝒌𝑻𝐓𝐍𝐅 Rate of Temp 
change irt TNF-𝛼, 	IL6	 and IL10 -  𝝉𝟏 Temp time constant hr-1 𝒌𝑻𝟔  𝒌𝑻 Temp rate of change - 𝒌𝑻𝟏𝟎  𝑻𝒃 Baseline and max 
Temp, respectively °C 𝜼𝑻𝐓𝐍𝐅 Half-max of TNF-𝛼, IL6 and IL10, resp. 
regulating Temp 
pg/mL 
 𝑻𝑴 𝜼𝑻𝟔     𝜼𝑻𝟏𝟎     𝒉𝑻𝐓𝐍𝐅 Exp. modulating TNF-𝛼, IL6	 and IL10, resp. effect on 
Temp 
- 
 𝒌𝐏𝐓 PT rate of change hr-1 𝒉𝑻𝟔  𝒌𝐏𝐓𝑬 Rate of PT change irt endotoxin kghr	ng 𝒉𝑻𝟏𝟎  𝐏𝐓𝒃 Baseline PT kPa 
       𝒌𝑵𝑴 𝑀c production rate of NO (hr noc)-1  𝒌𝑵 NO decay rate hr-1 𝜼𝑵𝐓𝐍𝐅 Half-max of TNF-𝛼 
and IL10, resp. 
regulating NO 
pg/mL 
 𝒉𝑵𝐓𝐍𝐅 Exp. modulating TNF-𝛼 and IL10, 
resp. effect on NO 
- 𝜼𝑵𝟏𝟎  𝒉𝑵𝟏𝟎 
       𝒌𝑹𝐏𝐓 Rate of Rs change irt 
PT and NO 
mmHg	minmL	hr	   𝜼𝑹𝑷𝑻 Half-max of PT regulating Rs kPa 𝒌𝑹𝑵  𝑹𝒃 Baseline Rs mmHg	minmL  𝒌𝑹 Rs decay rate hr-1     
       𝜼𝑯𝑻 Half-max of Temp regulating HR °C  𝝉𝟐 HR time constant hr-1 𝜼𝑯𝑷 Half-max of BP regulating HR bpm  𝒌𝑯 HR rate of change - 𝒉𝑯𝑻 Exp. modulating 
Temp and BP, resp. 
effect on HR 
- 
 𝑯𝒃 Baseline and max 
HR, respectively bpm 𝒉𝑯𝑷  𝑯𝑴 𝑩𝑷𝒃 Baseline BP mmHg     
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Table 2. Nominal parameter values. All parameters of the inflammatory sub-model were 
taken from (7). All other parameters (cardiovascular and regulatory sub-models) were taken 
from (6). Parameters derived from data are denoted by ⤉. Parameter denoted with ⥉ was 
taken from (20).  
 
Par. 
Value  
Par. 
Value 
Janum  
et al. (2016) 
Copeland 
et al. (2005) 
 Janum  
et al. (2016) 
Copeland 
et al. (2005) 
Inflammatory Sub-Model 𝒌𝑬 1.01  𝒌𝑴𝑹 0.006 𝒌𝑴 0.041  𝒌𝑴𝑨 2.51 𝒌𝑴𝐓𝐍𝐅 4.14E-06 7.99E-06⤉  𝒌𝐓𝐍𝐅 1 𝒌TNF𝑴 0.60 0.49⤉  𝒌𝟔 0.66 𝒌𝟔𝑴 0.81 0.92⤉  𝒌𝟖 0.66 𝒌𝟖𝑴 0.56 0.34⤉  𝒌𝟏𝟎 0.80 𝒌𝟏𝟎𝑴 0.0191  𝒘𝐓𝐍𝐅  1.12⤉ 0.81⤉ 𝒌𝟔𝐓𝐍𝐅 0.81 0.92⤉  𝒘𝐈𝐋𝟔 1.05⤉ 1.74⤉ 𝒌𝟖𝐓𝐍𝐅 0.56 0.34⤉  𝒘𝐈𝐋𝟖 3.01⤉ 1.22⤉ 𝒌𝟏𝟎𝟔 0.0191  𝒘𝐈𝐋𝟏𝟎 0.23⤉ 0.31⤉ 𝜼𝑴𝑬 3.30  𝒉𝑴𝑬 1 𝜼𝑴𝐓𝐍𝐅 100.00 81.20⤉  𝒉𝑴𝐓𝐍𝐅 3.16 𝜼𝟔𝐓𝐍𝐅 185.00 150.22⤉  𝒉𝟔𝐓𝐍𝐅 2 𝜼𝟖𝐓𝐍𝐅  𝒉𝟖𝐓𝐍𝐅 3 𝜼𝑴𝟏𝟎 4.35  𝒉𝑴𝟏𝟎 0.30 𝜼𝐓𝐍𝐅𝟏𝟎 17.39  𝒉𝐓𝐍𝐅𝟏𝟎 3 𝜼𝟔𝟏𝟎 34.77  𝒉𝟔𝟏𝟎 4 𝜼𝟖𝟏𝟎 17.39  𝒉𝟖𝟏𝟎 1.5 𝜼𝐓𝐍𝐅𝟔 
560.00 636.72⤉ 
 𝒉𝐓𝐍𝐅𝟔 2 𝜼𝟔𝟔  𝒉𝟔𝟔 1 𝜼𝟏𝟎𝟔  𝒉𝟏𝟎𝟔 3.68 𝑴¨ 3E+04    
Cardiovascular Sub-Model 𝑹𝒂 0.19  𝑬𝒍𝒂 0.81 𝑹𝒗 0.0027  𝑬𝒔𝒂 3.85 𝑬𝒎 0.0265  𝑬𝒍𝒗 0.0217 𝑬𝑴 3.20  𝑬𝒔𝒗 0.13 
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Table 2. (cont.) 
 
Par. 
Value  
Par. 
Value 
Janum  
et al. (2016) 
Copeland  
et al. (2005) 
 Janum  
et al. (2016) 
Copeland  
et al. (2005) 
Regulatory Sub-Model 𝒌𝑻𝐓𝐍𝐅 1.5  𝝉𝟏 1 𝒌𝑻𝟔 1.5  𝒌𝑻 0.5 𝒌𝑻𝟏𝟎 0.0625  𝑻𝒃 36.83⤉ 36.58⤉ 𝜼𝑻𝐓𝐍𝐅 185.00  𝑻𝑴 39.5⥉ 𝜼𝑻𝟔 560.00    𝜼𝑻𝟏𝟎 34.77    𝒉𝑻𝐓𝐍𝐅 0.75  𝒌𝐏𝐓 0.08 𝒉𝑻𝟔 0.75  𝒌𝐏𝐓𝑬 0.12 𝒉𝑻𝟏𝟎 1  𝐏𝐓𝒃 781.15⤉ 
     𝒌𝑵𝑴 0.0020 0.0018  𝒌𝑵 0.045 0.025 𝜼𝑵𝐓𝐍𝐅 95 70  𝒉𝑵𝐓𝐍𝐅 2 𝜼𝑵𝟏𝟎 4  𝒉𝑵𝟏𝟎 0.4 
     𝒌𝑹𝐏𝐓 30 14  𝜼𝑹𝑷𝑻 230.00 100.00 𝒌𝑹𝑵 1.40 1.65  𝑹𝒃 1.03 0.99 𝒌𝑹 5.4 6.0    
     𝜼𝑯𝑻 36.5 36.39  𝝉𝟐 0.9 0.35 𝜼𝑯𝑷 143.00 107.34  𝒌𝑯 0.21 0.20 𝒉𝑯𝑻 2  𝑯𝒃 60.36 64.29 𝒉𝑯𝑷 4  𝑯𝑴 207 𝑩𝑷𝒃 118.40 121.97    
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Table 3. Optimal parameter values. 
 
Par. 
Optimal Value  
Par. 
Optimal Value 
Janum  
et al. (2016) 
Copeland  
et al. (2005) 
 Janum  
et al. (2016) 
Copeland  
et al. (2005) 
Inflammatory Sub-Model 𝒌𝟏𝟎 0.83 0.65  𝒌𝟖𝑴 0.46 0.15 𝒌𝟏𝟎𝑴 0.01 0.01  𝒌𝐓𝐍𝐅 1.00 1.01 𝒌𝟔 0.81 1.02  𝒌𝐓𝐍𝐅𝑴 0.60 0.56 𝒌𝟔𝑴 0.72 0.93  𝒌𝑬 1.01 1.02 𝒌𝟖 0.74 1.21     
Cardiovascular Sub-Model 𝑹𝒃 1.03 0.99  𝑬𝒍𝒂 0.79 0.80 
Regulatory Sub-Model 𝝉𝟏 1.38 2.12  𝝉𝟐 0.79 0.32 𝒌𝑻𝟔 2.19 2.41  𝒌𝑯 0.20 0.20 𝒌𝑹𝐏𝐓 12.97 13.18  𝒌𝑹𝑵 0.80 1.61 𝒌𝑹 4.28 6.60  𝒌𝐏𝐓𝑬 0.12 - 𝒌𝑷𝑻 0.06 -     
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Figure Captions 
 
Fig 1. Experimental Protocol. Immune mediators (TNF-𝛼, IL-6, IL-8), temperature, heart rate, and 
blood pressure were periodically collected during the (A) Copeland and (B) Janum studies. Note 
that pain perception threshold and IL-10 were only recorded in the study by Janum et al. and heart 
rate was continuously recorded. 
 
Fig 2. Feedback diagram for human response to endotoxin challenge. LPS administration initiates 
an immune cascade, as well as a decrease in the pain perception threshold. The decrease in pain 
perception threshold results in an increase in blood pressure (BP). Pro-inflammatory cytokines act 
as pyrogens, increasing body temperature while anti-inflammatory cytokines act as anti-pyrogens 
to decrease temperature. Pro- and anti-inflammatory cytokines have opposing effects on nitric 
oxide production, which decreases BP via vasodilation (decreases vascular resistance). 
Temperature increases heart rate (HR). BP decreases HR, via changes in vagal tone, in the case of 
normotension.  When BP falls to a hypotensive range, it will act to increase HR. The changes in 
HR via BP are temperature-dependent. 
 
Fig 3. Immune interactions in response to endotoxin challenge. Endotoxin (E) administration 
results in the activation of monocytes (MR→MA). Activated monocytes (MA) secrete mediators 
that induce further immune activation (TNF-α, IL-6, and IL-8). These pro-inflammatory mediators 
stimulate the production of IL-10, which regulates the immune response as an anti-inflammatory 
mediator. IL-6 also exhibits anti-inflammatory effects as it downregulates the synthesis of TNF-α 
and its own release. 
 
Fig 4. Cardiovascular model. The cardiovascular system is comprised of the small and large 
arteries and veins (subscripts sa, la, sv, lv). Each compartment has an associated blood 
pressure p (mmHg), volume V (mL), and elastance E (mmHg/mL). Flow between compartments 
are represented by qi (s/mL), with a corresponding resistance Ri (mmHg s/mL) with subscripts (a, 
s, v) representing arteries, veins, and peripheral vasculature. 
 
 
Fig 5. Model fits to data. Fits to experimental data from study by Copeland et al. (A-B) and Janum 
et al. (C-D). Endotoxin (2 ng/kg) was administered at time 𝑡 = 0 and inflammatory mediator 
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response, temperature, heart rate, and blood pressure were recorded over 9 hours (A-B) and 6 hours 
(C-D). 
 
Fig 6. Effect on heart rate dynamics of temperature alone and of temperature and blood pressure 
as independent effects for the (A) Copeland and (B) Janum studies. Temperature alone (blue 
curves) results in an increase in heart rate, however it is not sufficient alone to return heart rate to 
its baseline level. Including temperature and blood pressure as independent effects (red curves) 
also does not fully capture the dynamics of the observed heart rate response. 
 
Fig 7. Effect of antibiotics, antipyretics, and vasopressors on cardio-inflammatory response. After 
inducing an infection via a constant endotoxin (black curve) (A), interventions were simulated at 𝑡 = 4 (red dashed line). The infection causes (B) a slight decrease in temperature and (C) a 
dramatic decrease in the pain perception threshold. (D) Nitric oxide rises in response to the 
infection and does not respond to any intervention. (E) The resistance increases in response to the 
infection, resulting in (F) an increase in blood pressure and a subsequent (G) decrease in heart rate. 
Antibiotics (blue curves) result in a decrease in the endotoxin, pain relief (increase in PT), fever 
reduction, and heart rate normalization (the increase in heart rate between 𝑡 = 4.5 and 𝑡 = 5 is due 
to blood pressure being in the hypotensive range during that time). Antipyretics do not affect the 
endotoxin; however, they induce pain relief and decrease fever and heart rate. They are unable to 
counter hypotension. Similar to antipyretics, vasopressors do not affect the endotoxin. While they 
do not alleviate fever, pain, or abnormally high heart rate, they are able to normalize blood 
pressure. 
 
Fig 8. Effect of multimodal treatment on cardio-inflammatory response. (A) Administering 
multimodal treatment at 𝑡 = 4 effectively relieves (B) pain and (C) allows temperature, (E) blood 
pressure, and (F) heart rate to return to their baseline levels. 
 
Fig S1. Effect of infection on inflammatory system. Infection (black curves) results in an increase 
in (A) all inflammatory mediators and (B) a dramatic decrease in the resting monocytes, resulting 
in an increase in the active monocytes. 
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Fig. 1. Experimental Protocol. Immune 
mediators (TNF-𝛼, IL-6, IL-8), temperature, 
heart rate, and blood pressure were periodically 
collected during the (A) Copeland and (B) 
Janum studies. Note that pain perception 
threshold and IL-10 were only recorded in the 
study by Janum et al. and heart rate was 
continuously recorded. 
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Fig. 2. Feedback diagram for 
human response to endotoxin 
challenge. LPS administration 
initiates an immune cascade, 
as well as a decrease in the 
pain perception threshold. The 
decrease in pain perception 
threshold results in an 
increase in blood pressure 
(BP). Pro-inflammatory 
cytokines act as pyrogens, 
increasing body temperature 
while anti-inflammatory 
cytokines act as anti-pyrogens 
to decrease temperature. Pro- 
and anti-inflammatory 
cytokines have opposing 
effects on nitric oxide 
production, which decreases 
BP via vasodilation 
(decreases vascular 
resistance). Temperature 
increases heart rate (HR). BP 
decreases HR, via changes in 
vagal tone, in the case of 
normotension.  When BP falls 
to a hypotensive range, it will 
act to increase HR. The 
changes in HR via BP are 
temperature-dependent. 
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Fig. 3. Immune interactions in response to 
endotoxin challenge. Endotoxin (E) 
administration results in the activation of 
monocytes (MR→MA). Activated monocytes 
(MA) secrete mediators that induce further 
immune activation (TNF-α, IL-6, and IL-8). 
These pro-inflammatory mediators stimulate the 
production of IL-10, which regulates the immune 
response as an anti-inflammatory mediator. IL-6 
also exhibits anti-inflammatory effects as it 
downregulates the synthesis of TNF-α and its own 
release. 
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Fig. 4. Cardiovascular model. The 
cardiovascular system is comprised of the small 
and large arteries and veins (subscripts sa, la, sv, 
lv). Each compartment has an associated blood 
pressure p (mmHg), volume V (mL), and 
elastance E (mmHg/mL). Flow between 
compartments are represented by qi (s/mL), with 
a corresponding resistance Ri (mmHg s/mL) with 
subscripts (a, s, v) representing arteries, veins, 
and peripheral vasculature. 
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Fig. 5. Model fits to data. Fits to experimental data from study by Copeland et al. (A-B) and 
Janum et al. (C-D). Endotoxin (2 ng/kg) was administered at time 𝑡 = 0 and inflammatory 
mediator response, temperature, heart rate, and blood pressure were recorded over 9 hours (A-
B) and 6 hours (C-D). 
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Fig. 6. Effect on heart rate dynamics of 
temperature alone and of temperature and blood 
pressure as independent effects for the (A) 
Copeland and (B) Janum studies. Temperature 
alone (blue curves) results in an increase in heart 
rate, however it is not sufficient alone to return 
heart rate to its baseline level. Including 
temperature and blood pressure as independent 
effects (red curves) also does not fully capture the 
dynamics of the observed heart rate response. 
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Fig. 7. Effect of antibiotics, antipyretics, and vasopressors on cardio-inflammatory response. 
After inducing an infection via a constant endotoxin (black curve) (A), interventions were 
simulated at 𝑡 = 4 (red dashed line). The infection causes (B) a slight decrease in temperature 
and (C) a dramatic decrease in the pain perception threshold. (D) Nitric oxide rises in response 
to the infection and does not respond to any intervention. (E) The resistance increases in 
response to the infection, resulting in (F) an increase in blood pressure and a subsequent (G) 
decrease in heart rate. Antibiotics (blue curves) result in a decrease in the endotoxin, pain relief 
(increase in PT), fever reduction, and heart rate normalization (the increase in heart rate 
between 𝑡 = 4.5 and 𝑡 = 5 is due to blood pressure being in the hypotensive range during that 
time). Antipyretics do not affect the endotoxin; however, they induce pain relief and decrease 
fever and heart rate. They are unable to counter hypotension. Similar to antipyretics, 
vasopressors do not affect the endotoxin. While they do not alleviate fever, pain, or abnormally 
high heart rate, they are able to normalize blood pressure. 
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Fig 8. Effect of multimodal treatment on cardio-inflammatory response. (A) Administering 
multimodal treatment at 𝑡 = 4 effectively relieves (B) pain and (C) allows temperature, (E) 
blood pressure, and (F) heart rate to return to their baseline levels. 
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Fig. S1. Effect of infection on inflammatory 
system. Infection (black curves) results in an 
increase in (A) all inflammatory mediators and 
(B) a dramatic decrease in the resting monocytes, 
resulting in an increase in the active monocytes. 
 
